EditorialOpen Access · CC BY 4.0
Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies
Frontiers in Oncology · 18.08.2026 · 16
DOI: 10.3389/fonc.2026.1936446 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Oncology, online erschienen am 18.08.2026. Verfasst von Yangmin Zhu. Beteiligte Einrichtung: The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
bispecific antibodieschimeric antigen receptorhematologic malignanciesleukemialymphomamyeloma
Autor:innen und Institutionen
- The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China.
Zitieren
APA
Zhu, Y. (2026). Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1936446
Vancouver
Zhu Y. Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1936446
BibTeX
@article{Zhu2026,
author = {Zhu, Yangmin},
title = {Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1936446}
}
EUVIMED